Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.

MLA

Ball, William A., et al. “Addition of an NK1 Receptor Antagonist to an SSRI Did Not Enhance the Antidepressant Effects of SSRI Monotherapy: Results from a Randomized Clinical Trial in Patients with Major Depressive Disorder.” Human Psychopharmacology: Clinical & Experimental, vol. 29, no. 6, Nov. 2014, pp. 568–77. EBSCOhost, https://doi.org/10.1002/hup.2444.

APA

Ball, W. A., Snavely, D. B., Hargreaves, R. J., Szegedi, A., Lines, C., & Reines, S. A. (2014). Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Human Psychopharmacology: Clinical & Experimental, 29(6), 568–577. https://doi.org/10.1002/hup.2444

Chicago

Ball, William A., Duane B. Snavely, Richard J. Hargreaves, Armin Szegedi, Christopher Lines, and Scott A. Reines. 2014. “Addition of an NK1 Receptor Antagonist to an SSRI Did Not Enhance the Antidepressant Effects of SSRI Monotherapy: Results from a Randomized Clinical Trial in Patients with Major Depressive Disorder.” Human Psychopharmacology: Clinical & Experimental 29 (6): 568–77. doi:10.1002/hup.2444.